

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal (STA)

### Methylalntrexone bromide for treating opioid induced constipation [ID700]

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Swedish Orphan Biovitrum (methylalntrexone bromide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Black Health Agency</li> <li>• Bladder and Bowel Foundation</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• IBS Network</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Britain</li> <li>• Pain Concern</li> <li>• Pain Relief Foundation</li> <li>• Pain UK</li> <li>• Promocon</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• Association of Coloproctology of Great Britain and Ireland</li> <li>• Association for Continence Advice</li> <li>• Association for Palliative Medicine</li> <li>• British Geriatrics Society</li> <li>• British Pain Society</li> <li>• British Psychosocial Oncology Society</li> <li>• British Society of Gastroenterology</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (naloxegol)</li> <li>• Actavis UK (glycerol suppositories, bisacodyl)</li> <li>• Boehringer Ingelheim (bisacodyl, docusate, macrogol, sodium picosulphate)</li> <li>• Cardinal Health Martindale Products (glycerol suppositories)</li> <li>• Laboratorios Casen Fleet (sodium dihydrogen phosphate dehydrate, disodium hydrogen phosphate dodecahydrate enema)</li> <li>• Chanelle Medical (bisacodyl, macrogol)</li> <li>• Chatfield Pharmaceuticals (bisacodyl)</li> <li>• Chemidex Pharma (phosphate enema, arachis oil enema)</li> <li>• Hermal (ispaghula husk, glycerol)</li> </ul>

National Institute for Health and Care Excellence  
 Matrix for the technology appraisal of methylalntrexone bromide for treating opioid induced constipation [ID700]

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Cancer Research UK</li> <li>• Primary Care Society for Gastroenterology</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Health Forum</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Bath and North East Somerset CCG</li> <li>• NHS Wiltshire CCG</li> <li>• Welsh Government</li> </ul>	<p>suppositories)</p> <ul style="list-style-type: none"> <li>• Medreich (bisacodyl)</li> <li>• Meda Pharmaceuticals (macrogol)</li> <li>• Napp Pharmaceuticals Limited (naloxone-oxycodone)</li> <li>• Norgine Pharmaceuticals (sterculia/frangula, macrogol, docusate sodium enema)</li> <li>• Orbis Consumer Products (glycerol suppositories)</li> <li>• Pinewood Healthcare (sodium citrate enema)</li> <li>• Thornton &amp; Ross (macrogol, magnesium hydroxide, glycerol suppositories)</li> <li>• UCB Pharma (sodium citrate enema, docusate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group</li> <li>• CORE (Digestive Disorders Foundation)</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS***

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that markets comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup>Non-company consultees are invited to submit statements relevant to the group they are representing.